Shares of Bristol Myers Squibb Co. BMY rallied 1.03% to $56.80 Monday, on what proved to be an all-around mixed trading ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback